Assessment of Safety and Effectiveness of Desoximetasone Emollient Cream 0.25% in Comparison to Mometasone Cream 0.1% in Patients with Eczema: MCOR Study

Emcure Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Who are capable of complying with protocol
•requirements
•2. Newly diagnosed, treatment-naÃ¯ve patients with clinical diagnosis of eczema
•3. Patients treated with desoximetasone 0.25% emollient cream or mometasone cream
•0.1% as per dermatologistâ??s discretion and approved Prescribing Information
•4. Patients/ Legally Authorized Representative (LAR) willing to give written informed

•1. Patients with history of hypersensitivity to any of the components of study medication
•preparations.
•2. Pregnant and nursing women
•3. Patients with documented comorbid systemic disorders of the cardiovascular, central
•nervous, gastrointestinal, respiratory systems, hormonal disorders, and chronic
•inflammatory conditions, which, in the opinion of the investigator may have a potential
•health risk to the patient.
•4. Patients consuming oral immunosuppressive medications including oral
•corticosteroids, etc prior to 3 weeks of study.
•5. Patients with documented disorders related to present or past history of abnormal
•activity of Hypothalamo-pituitary-adrenal axis.

发起方